Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Investigational Unadjuvanted RSV Maternal Vaccine Compared to Placebo When Administered to Healthy Non-pregnant Women.

Next Previous
Trial Profile

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Investigational Unadjuvanted RSV Maternal Vaccine Compared to Placebo When Administered to Healthy Non-pregnant Women.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2019

At a glance

  • Drugs GSK-3888550A (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions; First in man
  • Sponsors GlaxoSmithKline

    • Most Recent Events

    • 21 Nov 2018 Planned End Date changed from 26 Sep 2019 to 19 Sep 2019.
    • 21 Nov 2018 Planned primary completion date changed from 29 Apr 2019 to 22 Apr 2019.
    • 21 Nov 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top